Developing Medical Technologies that solve unmet clinical needs and have a substantial market opportunity Odyssey Health (OTCMKTS:ODYY)
Odyssey Health
Odyssey Health Inc is a biomedical company focused on acquiring, developing and commercializing life-saving medical technologies and drugs that have superior clinical utility and a substantial market opportunity.
Pharmaceuticals
PRV-002:Novel compound for treatment of concussion which currently has no FDA approved drug. PRV-001: Novel compound intended to treat Niemann-Pick disease; potential Orphan Drug designation
CardioMap
Heart monitoring and screening device for early detection of coronary artery disease. CardioMap is more sensitive than EKG’s; captures low-level electrical signals that EKG’s don’t pick up
Save-A-Life
Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical, anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds without harm
Odyssey Health, Inc. (OTC:ODYY) - A company focused on developing unique, life-enhancing medical products Concussion Drug Development Program
Concussion Related Medical costs is $20 Billion per year in US - $400B worldwide
CardioMap System Heart Monitoring and Screening Device
Save - A -Life Choking Rescue Device
Key Corporate & Product Development Highlights - Sleeping Giant ?
Odyssey is currently communicating with the FDA to present the findings from the Phase I trial. Phase II trial sites are being identified and study design is being created
Odyssey is currently communicating with the FDA to present the findings from the Phase I trial. Phase II trial sites are being identified and study design is being created with the site’s medical leadership and the Odyssey Medical Advisors.
- Odyssey acquired the intellectual property and all rights to the drug on March 1, 2021. Since the acquisition Odyssey has made significant progress in the development program. Some key success points are:
- Successful completion of the pre-clinical toxicology program.
- Created a Scientific Advisory Board of renowned medical doctors who evaluated our drug technology, pre-clinical studies and are overseeing the clinical trials.
- Successful development of a nanoparticle drug formulation.
- Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
- Successful development of a spray-dried formulation for intranasal delivery with our partner Upperton Ltd based in the UK.
- Successful development and GMP manufacture of a novel breath-propelled intranasal delivery device with our partner, Design Catapult, Inc.
- The novel breath-propelled intranasal delivery device proved successful in the Phase I trial.
- Filed a patent application on the unique breath-propelled intranasal delivery device.
- Contracted with world-class contract research organizations, Avance Clinical Pty, Ltd. and Nucleus Networks to conduct the Phase I human trial.
- Obtained Alfred Ethics Board approval of an Investigators Brochure to conduct the clinical trial.
- Successful submission of clinical trial protocols to clinicaltrials.gov.
- Ongoing drug stability of the drug in the intranasal device without degradation.
- Successfully completed the Phase I human clinical trial proving the drug is safe and well tolerated.
- Created a Military Advisory Board with distinguished military veterans to assist us in selecting military sites for Phase II clinical trial.
PRV-002
Novel Compound for Treatment
of Concussion
FDA APPROVAL COULD BE HUGE!
Great Opportunity - Trading Closer To Its 52-week Low With The Overall Market ROUT - Significant Upside Potential !
Internationally Acclaimed Scientific Advisory Committee
James P. Kelly, MA, MD, FAAN, FANA
Dr. Kelly is the Executive Director of the Marcus Institute for Brain Health (MIBH) and Professor of Neurology at the University of Colorado Anschutz Medical Campus in Aurora, CO. The MIBH is a specialized treatment program funded by the Marcus Foundation to care for US military Veterans with persistent symptoms of TBI. He is also National Director of the Gary Sinise Foundation Avalon Network TBI Medical Programs for which the MIBH serves as the clinical coordinating center. https://www.odysseyhealthinc.com/scientific-advisory-board
Dallas C. Hack, MD, MPH, FACMPH, COL, US Army
Dr. Dallas C. Hack graduated from Loma Linda University School of Medicine in 1976. From 2008 to 2014, COL(R) Hack was the Director of the Combat Casualty Care Research Program (CCCRP) where he led trauma research across the Department of Defense, with a focus on Traumatic Brain Injury (TBI). He oversaw 650 TBI research projects and over $850 million in federal funds for TBI research. COL(R) Hack helped establish the 2013 National Research Action Plan on TBI and PTSD, the Chronic Effects of Neurotrauma Consortium, and the NCAA-DoD Grand Alliance.
Meet: Military Advisory Board
James Linder
Jim Linder is a recognized leader in the world of Special Operations and Intelligence organizations as a high performing and skilled strategist. He was a U.S. General Officer with over three decades of direct command leadership around the globe.
Francis Beaudette
Over the course of his 32-year career in Army and Joint assignments, the majority of it as a Green Beret, Francis “Fran” M. Beaudette served with high performing organizations at varying levels, from a 12-man Special Forces ‘A-team’ to the 36,000-Soldier and Civilian U.S. Army Special Operations Command.
Paul Toolan
Lieutenant Colonel (LTC) Paul Toolan joined the Army as a Private in 1986. Over the course of more than three decades in uniform, he has risen through the ranks and completed every elite school in the U.S. Army. He is a Special Forces Airborne Ranger and started his Special Forces career as a Detachment Commander in 3rd Special Forces Group at Fort Bragg.
Timothy Szymanski
Vice Admiral (r) Szymanski has led and served in many Navy and Joint Special Operations assignments as a Navy Special Warfare Officer (SEAL) for over 36 years. He most recently served as the Deputy Commander for United States Special Operations Command (USSOCOM) after serving as the Commander of Naval Special Warfare (NSW).
Start Your Research Now ! Remember: Early Bird Gets The WORM! Odyssey Health (OTCMKTS:ODYY)
Disclaimer:This website / media webpage is owned, operated and edited by Investor Brand Media. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “IBM” refers to Investor Brand Media. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. IBM business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IBM often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Investor Brand Media has been compensated seven hundred and fifty dollars by a 3rd party Bullyzeye Media LLC for creation of this landing page on ODYY.
References: https://finance.yahoo.com/news/odyssey-health-inc-announces-successful-123000424.html
https://www.odysseyhealthinc.com/investor-relations
